In vitro estrogen-binding by human breast carcinomas.

Area of Science:

• Oncology
• Endocrinology
• Biochemistry

Background:

• Hormonal therapy is a key treatment for estrogen receptor-positive breast cancer.
• Predicting patient response to hormonal therapy is crucial for effective treatment planning.
• Estrogen receptor (ER) levels in breast tumors are a primary indicator for ER-targeted therapies.

Purpose of the Study:

• To evaluate the correlation between estrogen-binding capacity in breast carcinomas and patient response to hormonal manipulative therapy.
• To determine optimal methods for expressing estrogen-binding capacity for clinical utility.
• To assess the influence of menopausal status on estrogen-binding capacity.

Main Methods:

• In vitro measurement of estrogen-binding capacity in 106 breast carcinoma samples.
• Estradiol binding was quantified per milligram of tumor wet weight and per concentration of deoxyribonucleic acid (DNA).
• Comparison of binding capacities between pre- and postmenopausal women.

Main Results:

• Estrogen-binding capacity varied significantly, ranging from 0 to 1.3 fm/mg in premenopausal women and 0 to 16.8 fm/mg in postmenopausal women.
• Menopausal status and serum estrogen concentrations are important factors in classifying tumors as low or high estrogen-binding capacity.
• Expressing estradiol binding relative to DNA concentration may be a more reliable method than using wet weight.

Conclusions:

• Tumor estrogen-binding capacity is a critical factor in predicting response to hormonal therapy for recurrent breast cancer.
• Menopausal status should be considered when interpreting estrogen-binding capacity results.
• Standardizing the measurement and reporting of estrogen-binding capacity, potentially using DNA normalization, can improve clinical decision-making.